The effects of pioglitazone treatment on pancreatic cancer-related insulin resistance.

摘要: 329Background: Insulin resistance (IR) in pancreatic cancer (PC) patients is associated with cachexia and poor outcome. Pioglitazone (PIO) improves insulin sensitivity via activation of peroxisome proliferator-activated receptor (PPAR gamma). Effects PIO on sensitivity, glucose homeostasis, circulating adipokine levels PC have not been examined. Methods: Patients metastatic were administered 45mg/day orally for 8 weeks concurrent chemotherapy. known DM at enrollment identified Fasting plasma was collected baseline, 2, 4, 6, pioglitazone treatment 2 weeks-post treatment. The primary objective to describe changes indicators IR, including glucoregulatory hormone levels, tolerance, inflammatory cytokines. Results: Fourteen (age 64y), a mean BMI 28 enrolled. Mean adiponectin increased from baseline week (14.2± 3.3 46.9±11.4µg/ml, respectively, P ≤ 0.01), returned b...